Results 121 to 130 of about 2,285,787 (260)

LUNG CANCER TARGETED CHEMOTHERAPY VIA HERCEPTIN BASED CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED T CELL MEMBRANE COATED SYNTHETIC NANOPARTICLES [PDF]

, 2019
Cell membrane-derived nanoparticles recently caught attention due to their desirable features in drug delivery such as mimicking properties of native tissue and cells, avoiding systemic clearance, and alleviating foreign body responses.
Yaman, Serkan
core   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Status and future of recombinant adeno‐associated virus vector manufacturing

Biotechnology Progress, EarlyView.
Abstract Sixty years of adeno‐associated virus (AAV) research illustrates a trajectory marked by basic science exploration, iterative innovation, persistent challenges, a number of clinical setbacks, as well as commercial therapeutic triumphs. This continual evolution has led to recombinant AAV (rAAV) becoming a cornerstone of modern gene therapy ...
Frank Agbogbo, David Dismuke
wiley   +1 more source

From Caffeine to Aspirin: Everyday Molecules as Triggers for Genetically Encoded Proximity Systems

Chemistry – A European Journal, EarlyView.
This Perspective article highlights how familiar dietary ingredients and over‐the‐counter (OTC) drugs (such as caffeine and its metabolites, SA, and aspirin) can be repurposed as clinically translatable chemical triggers for genetically encoded proximity systems.
Mingguang Cui, Tianlu Wang, Yaoyu Han, Yun Huang, Tien‐Hung Lan, Yunbin Zhou   +5 more
wiley   +1 more source

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source

Chimeric antigen receptors

, 2015
A chimeric antigen receptor (CAR) comprising an extracellular spacer which comprises at least part of the extracellular domain of human low affinity nerve growth factor (LNGFR) or a derivative ...
BONINI, MARIA CHIARA, BONDANZA, ATTILIO, Casucci, Monica   +2 more
core  

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T

, 2018
Chimeric antigen receptor (CAR) T cell therapy represents the first U.S. Food and Drug Administration approved gene therapy and these engineered cells function with unprecedented efficacy in the treatment of refractory CD19 positive hematologic ...
Dok Yoon, Chong Kim, Jakub Tolar, Mark Osborn   +3 more
core   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting

Experimental Hematology & Oncology
Chimeric Antigen Receptor T-Cell (CAR-T) therapy demonstrates significant potential in the treatment of multiple myeloma (MM). However, resistance to CAR-T therapy remains a critical challenge.
Yuhan Hu, Jiangxue Hou, Zhongxing Jiang, Quande Lin   +3 more
doaj   +1 more source